Ongoing | Infectious Disease Accelerated Approvals Vaccines
The FDA’s Center for Biologics Evaluation and Research (CBER) has highlighted ongoing accelerated approvals for infectious disease vaccines specifically granted based on surrogate endpoints. This status tracking indicates the current landscape of biologic products utilizing this specific regulatory pathway.
This affects manufacturers of infectious disease vaccines, clinical operations teams managing surrogate endpoint validation, and regulatory professionals overseeing accelerated approval pathways for biological products.
The use of surrogate endpoints for vaccine approval suggests a regulatory reliance on markers predicted to correlate with clinical benefit when traditional outcome studies may be resource-intensive or prolonged. For industry professionals, this indicates the continued viability of the accelerated approval pathway for infectious diseases, though it necessitates rigorous post-market confirmatory trials to maintain market authorization.
Regulatory teams should monitor post-marketing requirement (PMR) timelines for candidates under this pathway and ensure clinical protocols are robust enough to eventually confirm clinical benefit as required for full approval. QA teams should verify that surrogate endpoint data integrity is maintained throughout the accelerated phase.
Biologic Accelerated Approvals Based on a Surrogate Endpoint
Open in openFDA / FDA.gov